Drugs / OLEANDRIN
OLEANDRIN
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01562301 | Jun 2014 → Jun 2016 | chemotherapy-induced toxicity, lung carcinoma | M.D. Anderson Cancer Center | Withdrawn | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OLEANDRIN | ChEMBL registry synonym — accepted as the source's own label CHEMBL4285883 ↗ |
| Known as | Anvirzel | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01562301 ↗ |
| Known as | NSC-692219 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4285883 ↗ |
| Modality | Small molecule | — CHEMBL4285883 ↗ |
| Route | Other | “Starting Cohort Dose: 6 mg/m2 given 3 times a day administered sublingually for a 21 day cycle.” NCT01562301 ↗ |